The presence of FLT3-ITD mutations either at diagnosis or driving AML relapse after VEN-AZA treatment, exhibits apparent therapeutic applications with triplet regimens targeting FLT3-ITD, highlighted in the future directions part of this work. The gene discussed is FLT3; the disease is acute myeloid leukemia.